Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma

Key clinical point: Elotuzumab-based maintenance may deepen response post transplant in MM.

Major finding: There was a combined complete response (CR) or very good partial response (VGPR) rate increase from 57.1% to 100% (CR = 3, VGPR = 4).

Study details: Retrospective evaluation of seven MM patients who were started on elotuzumab-based maintenance after transplant.

Disclosures: The study did not receive outside funding and the researchers reported that they had no disclosures.


Wang X et al. Blood Cells Mol Dis. 2020 Jul 28. doi: 10.1016/j.bcmd.2020.102482.